NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company that develops novel pharmaceuticals to address unmet medical needs in areas such as diabetic neuropathy and Alzheimer’s disease. The company’s lead drug, NB-01, is positioned for Phase III trials and has demonstrated promising efficacy and safety in treating diabetic neuropathic pain. This drug targets nerve growth factor release, which is vital for nerve stabilization and regeneration, addressing both the symptoms and underlying causes of the condition. The prevalence of diabetic peripheral neuropathy affects a significant portion of patients, and existing treatments often only provide symptom relief without addressing the disease itself. Additionally, NeuroBo is advancing NB-02, an Alzheimer's treatment currently in the IND-enabling stage, which has shown potential in preclinical models by targeting mechanisms like inhibition of acetylcholinesterase and amyloid-β. With an aging population contributing to a rising incidence of Alzheimer’s, NeuroBo aims to develop therapies that not only manage symptoms but also modify the disease progression.